about us

EHP Investment Criteria

Why Ellington?

Ellington Healthcare Partners-About Ellington Healthcare Partners-Criteria

Ellington Healthcare Partners uses our expertise in regenerative medicine, stem cell biology, immunology, oncology, and nanotechnology to identify opportunities in the treatment of a broad range of diseases. For example in oncology, EHP will evaluate novel cancer therapies, immunotherapy, new chemotherapies, targeted therapy, management of adverse consequences, and quality of life improvement.

Read More

Ellington Healthcare Partners I, L.P. (“EHP”) is an early-stage Venture Capital Fund targeting innovative bio-pharma developments. The Fund is chaired by Tommy G. Thompson, former Secretary of the U.S. Department of Health and Human Services. Dr. Anthony “Tony” Tether, the former Director of Defense Advanced Research Project Agency (DARPA), is the Chair of the Investment Committee.

Read More

Our integrated team of scientific, business and operational leaders has an outstanding track record of identifying and nurturing companies that are developing disruptive technologies. The team has chosen to target companies in the stem cell, regenerative medicine, and nanomedicine arena. These companies offer enormous potential in the fight to treat and cure cancer, cardiovascular disease, Alzheimer’s disease, diabetes, and develop applications that enable regenerative medicine to succeed.

Read More

contact

Ellington Healthcare Partners-Contact

In the USA and the Americas:
Granville A. Ungerleider
+1 (646) 450-5587
gu@nsipllc.com

Read More

Ellington Healthcare Partners seeks to be a lead or co-investor making commitments to early and mid-stage companies in investments in multi-stages up to $25 million. In the Bio-Pharma industry, this typically will characterize companies in Phase I or Phase II clinical trials.